Why the study?
The study was conducted to evaluate the therapeutic effects of coronary granulocyte colony-stimulating factor on rats with chronic ischemic heart disease.
Does G-CSF injection (subcutaneous or intracoronary) improve cardiac function and myocardial viability in rats with chronic ischemic heart disease?
Does G-CSF injection (subcutaneous or intracoronary) improve cardiac function and myocardial viability in rats with chronic ischemic heart disease?
Intracoronary and subcutaneous G-CSF injections improve cardiac function, reduce infarct size, and promote angiogenesis in a rat model of chronic ischemic heart disease.
Should not change clinical practice; leaves open human translation of G-CSF benefits in chronic ischemia.
Background The aim of this study was to evaluate the therapeutic effects of coronary granulocyte colony-stimulating factor (G-CSF) on rats with chronic ischemic heart disease (CIHD). Methods Thirty healthy rats were randomly divided into control, subcutaneous and intracoronary G-CSF injection groups ( n = 10) after the CIHD model was established. Left ventricular ejection fraction (LVEF), myocardial injury area, myocardial perfusion area and viable myocardium were observed by coronary angiography, dual-isotopic myocardial imaging and first-pass delayed myocardial perfusion magnetic resonance imaging (MRI) before modeling as well as 2 and 4 weeks after surgery. Results The peak times of peripheral blood and subcutaneous G-CSF levels were 3 and 5 days after mobilization, respectively. The peripheral blood CD34+/CD133+ cell ratio of subcutaneous or intracoronary G-CSF injection group significantly exceeded that of the control group ( P < 0.05). The distal stenosis degrees of target lesions in subcutaneous and intracoronary G-CSF injection groups were significantly lower than that of the control group ( P < 0.05). Compared with the situation before mobilization, LVEF was significantly improved after 2 weeks in intracoronary and subcutaneous G-CSF injection groups ( P < 0.01). Their infarcted myocardial areas were reduced, the left ventricular remodeling was relieved, the percentage of viable myocardium was increased, angiogenesis was promoted and cardiomyocyte apoptosis was inhibited. Conclusion Intracoronary G-CSF injection is safe and effective as subcutaneous injection, improving the cardiac function of CIHD rats.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: